A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2006
10/19/2006	WO2005105040A3 Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
10/19/2006	US20060235475 Implantable device using ultra-nanocrystalline diamond
10/19/2006	US20060235472 Therapy programming guidance based on stored programming history
10/19/2006	US20060235115 Bioadhesives comprising glycocalyx-containing fermentation residue for replacing phenol-formaldehyde components in plywood production
10/19/2006	US20060235114 Temperature-responsive hydrogel
10/19/2006	US20060235038 Novel therapeutic uses for nalmefene
10/19/2006	US20060234979 Inclusion complex in a beta-cyclodextrin, preferably, sulfobutyl ether beta-cyclodextrin, in the form of an injectable material; reducing irritation normally caused by aripiprazole at an intramuscular injection site; for treating schizophrenia
10/19/2006	US20060234977 Antiviral compostion comprising a sulphated glucose polymer and a bacteriostatic agent
10/19/2006	US20060234945 Ophthalmic therapeutic composition
10/19/2006	US20060234934 Composition and Method for Selective Cytostasis
10/19/2006	US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia
10/19/2006	US20060233885 Analgesic agent for newborn or fetal subjects
10/19/2006	US20060233883 Intravenous nanoparticles for targeting drug delivery and sustained drug release
10/19/2006	US20060233882 Osmotic dosage form
10/19/2006	US20060233881 Modified release dosage form
10/19/2006	US20060233880 Controlled release dosage forms
10/19/2006	US20060233879 Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, advantageous for delivering an ulcerative drug
10/19/2006	US20060233878 Extended release formulation of beta-lactam antibiotics
10/19/2006	US20060233877 Betaine compositions
10/19/2006	US20060233876 Compositions and methods for reducing cardiovascular morbidity and/or mortality
10/19/2006	US20060233875 Taste masked sumatriptan tablets and processes for their preparation
10/19/2006	US20060233874 Seamless capsule
10/19/2006	US20060233873 Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
10/19/2006	US20060233872 Pharmaceutical product which is used to reduced or stop moderate or severe snoring
10/19/2006	US20060233871 Transdermal delivery system for dried particulate or lyophilized medications
10/19/2006	US20060233870 Compositions and methods for drug delivery
10/19/2006	US20060233869 Biocompatible, oxidized cellulose particles of specific size; and porous water soluble or water swellable polysaccharide binder; controlling post-surgical bleeding; medical equipment
10/19/2006	US20060233868 Disinfectant Delivery System and Method of Providing Alcohol Free Disinfection
10/19/2006	US20060233867 Article of clothing for treating a tumor or the like
10/19/2006	US20060233866 Products comprising an applicator and a wax dispersion
10/19/2006	US20060233859 Methods for treating retinopathy with extended therapeutic effect
10/19/2006	US20060233853 Bone Growth Compositions and Methods
10/19/2006	US20060233845 Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics
10/19/2006	US20060233844 Method for the delivery of a biologically active agent
10/19/2006	US20060233843 Treatment of psychosis with a muscarinic m1 receptor ectopic activator
10/19/2006	US20060233842 Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
10/19/2006	US20060233841 Implantable gel compositions and method of manufacture
10/19/2006	US20060233839 Novel compounds
10/19/2006	US20060233830 Vaccines
10/19/2006	US20060233817 Peptide-based immunization therapy for treatment of atherosclerosis
10/19/2006	US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo
10/19/2006	US20060233783 Topical composition in the form of a gel for treating skin burns
10/19/2006	US20060233778 Stability for injection solutions
10/19/2006	US20060233758 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
10/19/2006	US20060233735 Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water.
10/19/2006	US20060233724 Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
10/19/2006	US20060233722 Antibacterial 5,5'-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy-1,1'-biphenyl compounds and related methods
10/19/2006	US20060233719 Delivery of antidepressants through an inhalation route
10/19/2006	US20060233718 heating drugs used for the treatment of anxiety or insomnia, coated on solid supports to form vapors and condensing the vapor to form aerosols comprising microstructure particles of the drugs
10/19/2006	US20060233717 Dosage form serotonin agonists comprising aerosols formed by heating layers of the drugs on solid supports, to form vapors, then condensing to form condensates which can be administered by breathing; prophylaxis of headaches, migraine
10/19/2006	US20060233716 Pharmaceutical formulations
10/19/2006	US20060233715 Compositions for nasal administration of drug
10/19/2006	US20060233714 Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions
10/19/2006	US20060233712 Magnetic nanoparticles
10/19/2006	US20060231452 Titration/compliance pack
10/19/2006	DE202004021099U1 Medical product useful to e.g. treat asthma, comprises a dry powder medicament dose (comprising fine particle dose of tiotropium and at least one dry excipient) loaded into a container for use in a dry powder inhaler
10/19/2006	DE202004021098U1 Pre-metered dry powder inhaler for moisture-sensitive medicaments e.g. tiotropium medicament, comprises dry powder medicament dose and container
10/19/2006	DE102005017777A1 Preparation of high fine particle suspension comprises dissolving solid in a solvent, freezing, lyophilizing solid matrix, withdrawing solid matrix from solvent and dispersing in an external phase and applying high power on the dispersion
10/19/2006	DE102005016981A1 Kombination zur Therapie bei benigner Prostatahyperplasie Combination for treatment of benign prostatic hyperplasia
10/19/2006	DE102005016873A1 New nano-particle useful for production of composition to treatment and/or prophylaxis of proliferative illnesses, cancer and bacterial infections, where nano-particle is bonded therapeutic substance
10/19/2006	DE102005016230A1 Vorrichtung zur Trockenvernebelung Apparatus for dry nebulization
10/19/2006	CA2605224A1 Combination for the therapy of benign prostatic hyperplasia
10/19/2006	CA2605153A1 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
10/19/2006	CA2604832A1 Medical devices and methods for producing the same
10/19/2006	CA2604770A1 Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof
10/19/2006	CA2604735A1 Nanoparticulate quinazoline derivative formulations
10/19/2006	CA2604327A1 Pharmaceutical aerosol composition
10/19/2006	CA2604192A1 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
10/19/2006	CA2604170A1 Rechargeable dermal patch
10/19/2006	CA2604028A1 Novel use of zinc gluconate for treating hydradenitis suppurativa
10/19/2006	CA2603987A1 Micelle composition of polymer and passenger drug
10/19/2006	CA2603842A1 Rnai therapeutic for respiratory virus infection
10/19/2006	CA2603783A1 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
10/19/2006	CA2603189A1 Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
10/19/2006	CA2603084A1 Nanoparticulate and controlled release compositions comprising cyclosporine
10/19/2006	CA2602268A1 Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
10/19/2006	CA2601990A1 Organic compounds
10/19/2006	CA2601864A1 Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
10/18/2006	EP1712240A1 Stable water-based medicinal preparation containing antibody
10/18/2006	EP1712237A2 Erythropoietin solution preparation stabilized with leucine, glutamic acid or lysine
10/18/2006	EP1712233A1 Aqueous solution containing pyrazoloacridone derivative
10/18/2006	EP1712224A1 Divisible rectangular flat tablet
10/18/2006	EP1712223A1 Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
10/18/2006	EP1712222A2 Pharmaceutical compositions providing enhanced drug concentrations
10/18/2006	EP1712221A1 Support accumulating in injured part in vascular channel
10/18/2006	EP1712220A1 Pharmaceutical aerosol composition
10/18/2006	EP1711220A1 Sublingual drug delivery device
10/18/2006	EP1711205A1 Synergistic liposomal adjuvants
10/18/2006	EP1711203A1 Targeted atherosclerosis treatment
10/18/2006	EP1711186A1 Slow release steroid composition
10/18/2006	EP1711178A1 Compositions substantially free of galactomannan containing piperacillin and tazobactam
10/18/2006	EP1711170A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
10/18/2006	EP1711169A1 Extended release coated microtablets of venlafaxine hydrochloride
10/18/2006	EP1711168A2 Oral pharmaceutical compositions of candesartan cilexetil
10/18/2006	EP1711167A1 Multiparticulate o-desmethylvenlafaxine salts and uses thereof
10/18/2006	EP1711166A1 Stable amorphous forms of montelukast sodium
10/18/2006	EP1711165A2 Membrane scaffold proteins
10/18/2006	EP1711164A2 Method of treating acute rhinosinusitis
10/18/2006	EP1711163A2 Dispersions prepared by use of self-stabilizing agents
10/18/2006	EP1711162A1 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method

1 ... 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 ... 2991